This article first appeared on GuruFocus.
Net Revenue: $7.4 million for Q2 2026, up from $6.7 million in Q2 2025.
Net Loss: $1.4 million, or $0.14 per share, compared to a net loss of $786,000 in Q2 2025.
AGGRASTAT Revenue: $661,000, down from $1.7 million in Q2 2025 due to generic competition.
ZYPITAMAG Revenue (Insurance Channel): $850,000, up from $751,000 in Q2 2025.
Marley Drug Revenue: $3.4 million, up from $3.1 million in Q2 2025.
ZYPITAMAG Revenue through Marley Drug: $1.3 million, up from $908,000 in Q2 2025.
Gateway Medical Pharmacy Revenue: $709,000, compared to $764,000 in Q2 2025.
West Olympia Pharmacy Revenue: $1.8 million, compared to $328,000 in Q2 2025 (acquired June 16, 2025).
Cost of Goods Sold: $4.2 million, up from $3.2 million in Q2 2025.
Selling Expenses: $2.8 million, up from $2.1 million in Q2 2025, including a $864,000 CMS rebate liability.
General and Administrative Expenses: $1.2 million, down from $1.3 million in Q2 2025.
Research and Development Expenses: $608,000, down from $741,000 in Q2 2025.
Adjusted EBITDA: $172,000, compared to negative $28,000 in Q2 2025.
Cash Position: $1.8 million as of June 30, 2026, down from $3.8 million at December 31, 2025.
Warning! GuruFocus has detected 6 Warning Signs with MCUJF.
Is MCUJF fairly valued? Test your thesis with our free DCF calculator.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Total net revenue increased to $7.4 million in Q2 2026 from $6.7 million in Q2 2025, driven by growth in ZYPITAMAG and pharmacy acquisitions.
ZYPITAMAG revenue through the traditional insurance channel rose to $850,000 from $751,000 year-over-year, reflecting higher formulary utilization.
Marley Drug revenue grew to $3.4 million from $3.1 million, with ZYPITAMAG sales through this channel increasing to $1.3 million from $908,000.
Adjusted EBITDA improved to $172,000 from a negative $28,000 in the prior year quarter, indicating better operational efficiency.
The company has no debt on its books, providing financial stability for ongoing operations and R&D investments.
Net loss widened to $1.4 million from $786,000 in Q2 2025, impacted by a $864,000 rebate liability from a CMS assessment.
AGGRASTAT revenue declined significantly to $661,000 from $1.7 million due to increased competition from generic tirofiban hydrochloride.
Cash balance decreased to $1.8 million from $3.8 million at the end of 2025, driven by working capital changes and acquisition payments.
Selling expenses increased to $2.8 million from $2.1 million, partly due to the CMS rebate liability and the West Olympia acquisition.
Research and development expenses, while lower, remain a significant cash outflow at $608,000, with no immediate revenue contribution from MC1.
Q: What were the key drivers behind the company's net loss for Q2 2026, and how did revenue performance vary across its different business segments?A: Dr. Albert Friesen (CEO) and James Kinley (CFO) explained that the net loss of $1.4 million was primarily due to a $864,000 rebate liability recorded in selling expenses related to a Centers for Medicare and Medicaid Services (CMS) assessment, $608,000 invested in R&D for MC1, and a non-cash amortization of $669,000 on assets from the ZYPITAMAG and pharmacy acquisitions. Revenue increased to $7.4 million from $6.7 million, driven by growth in ZYPITAMAG and the pharmacy segment, which offset a decline in AGGRASTAT sales.
Q: Can you provide more details on the decline in AGGRASTAT revenue and the company's strategy to address it?A: James Kinley (CFO) noted that AGGRASTAT net revenue fell to $661,000 from $1.7 million year-over-year due to lower unit volumes from increased competition by generic tirofiban hydrochloride. He highlighted that Medicure remains the only manufacturer of the 3.75-milligram bolus vial format and plans to remain price competitive in targeted ways while continuing to support US hospital accounts.
Q: How is ZYPITAMAG performing in the traditional insurance channel, and what is the company's primary focus for this product?A: James Kinley (CFO) reported that ZYPITAMAG net revenue through the traditional insurance channel increased to $850,000 from $751,000, driven by higher utilization through insurance formularies. He emphasized that the primary focus remains growing ZYPITAMAG revenue through both the insured channel and Marley Drug, noting that sales to Marley Drug are excluded from the traditional channel figures.
Q: What is the significance of the Marley Drug channel for ZYPITAMAG and other products?A: James Kinley (CFO) stated that Marley Drug net revenue increased to $3.4 million from $3.1 million, with ZYPITAMAG sales through Marley Drug rising to $1.3 million from $908,000. He explained that the direct distribution strategy through Marley Drug mitigates pressures from wholesaler fees, coverage gaps, lower PBM reimbursement rates, and product returns, making it a more efficient and controlled channel. It also enables expansion of access to other exclusive products like BRENZAVVY.
Q: How are the recent pharmacy acquisitions (Gateway Medical and West Olympia) contributing to the company's financials?A: James Kinley (CFO) detailed that Gateway Medical Pharmacy generated $709,000 in revenue for the quarter, compared to $764,000 in the prior year period. West Olympia Pharmacy contributed $1.8 million in revenue, a significant increase from $328,000 in the prior year, though the prior year figure only reflected revenue from its acquisition date of June 16, 2025. He noted the company is seeing improvements in inventory purchasing and is looking to capitalize on synergies from these acquisitions.
Q: What is the current status of the MC1 Phase 3 trial for PNPO deficiency, and what are the potential benefits?A: Dr. Albert Friesen (CEO) provided an update, stating that enrollment is ongoing with patients receiving treatment. He mentioned one patient has completed three years of treatment, one at two years, and a few at 12 months. The company is about to wrap up the enrollment phase and will then focus on collecting data and filing. He reiterated that MC1 has received fast track designation from the FDA, and if successful, could lead to a priority review voucher, which can be redeemed or sold for significant value.
Q: Can you elaborate on the new chemical entity (NCE) acquisition and its potential impact?A: Dr. Albert Friesen (CEO) confirmed that Medicure signed an asset purchase agreement for a patent and intellectual property related to new chemical entities. He stated that these NCEs hold promise for improvements over existing lead compounds for diseases Medicure is targeting. While the clinical therapeutic target has not yet been announced, preclinical testing and API drug development have commenced, and these could provide significant long-term value upon completion of all required studies and regulatory approval.
Q: What were the main reasons for the increase in selling expenses and the change in adjusted EBITDA?A: James Kinley (CFO) explained that selling expenses increased to $2.8 million from $2.1 million, primarily due to the CMS rebate liability and the acquisition of West Olympia Pharmacy, offset by decreases in consulting and marketing expenses. Adjusted EBITDA improved to $172,000 from negative $28,000, driven by increased net revenue from ZYPITAMAG and the Pharmacy Business segment, partially offset by lower AGGRASTAT revenue and higher cost of goods sold.
Q: How is the company's cash position, and what are the primary uses of cash?A: James Kinley (CFO) reported that cash totaled $1.8 million as of June 30, 2026, a decrease from $3.8 million at December 31, 2025. The decrease is primarily attributable to working capital changes, including inventory purchases and a payment pertaining to the Gateway Pharmacy acquisition. He also confirmed that the company has no debt on its books.
Q: What are the company's strategic priorities moving forward?A: Dr. Albert Friesen (CEO) outlined that the five focuses of the business are: sales of AGGRASTAT, growing ZYPITAMAG, the Marley Drug and pharmacy business, development of MC1 for PNPO deficiency, and the new chemical entity related to Medicure's legacy drug. He emphasized the goal is to grow the business, diversify revenue and asset base near-term through acquisitions, and long-term through R&D, with a stable long-term outlook to generate value for shareholders.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.